Sumitomo Pharma Co., Ltd. (TYO:4506)
Japan flag Japan · Delayed Price · Currency is JPY
2,475.50
-457.50 (-15.60%)
At close: Feb 20, 2026

Revenue by Segment

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period Ending
Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 Mar '19 Mar '18 Mar '17 Mar '16
Pharmaceuticals - Japan
99.84B114.66B126.16B149.98B152.57B
Pharmaceuticals - Japan Growth
-12.92%-9.12%-15.88%-1.70%9.17%
Pharmaceuticals - Asia
47.18B40.86B---
Pharmaceuticals - Asia Growth
15.46%----
Pharmaceuticals - North America
251.81B159.04B328.47B319.79B281.49B
Pharmaceuticals - North America Growth
58.34%-51.58%2.71%13.60%7.32%
Pharmaceuticals - China
--39.40B38.30B27.83B
Pharmaceuticals - China Growth
--2.87%37.60%-2.71%
Pharmaceuticals - Other Overseas
--16.75B12.18B17.23B
Pharmaceuticals - Other Overseas Growth
--37.58%-29.34%16.55%
Other Business
--44.88B39.90B36.94B
Other Business Growth
--12.50%8.00%-1.28%
Elimination of Intersegment Transactions
---120.00M-101.00M-116.00M
Total
398.83B314.56B555.54B560.04B515.95B
Total Growth
26.79%-43.38%-0.80%8.54%6.88%

Revenue by Geography

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period Ending
Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 Mar '19 Mar '18 Mar '17 Mar '16
Japan
92.59B107.34B170.61B222.88B192.61B
Japan Growth
-13.74%-37.08%-23.45%15.72%6.60%
North America (Excl. United States)
2.46B2.63B3.20B4.77B4.84B
North America (Excl. United States) Growth
-6.39%-17.92%-32.82%-1.55%-6.92%
United States of America
243.55B152.55B325.89B282.52B275.59B
United States of America Growth
59.65%-53.19%15.35%2.51%7.47%
Others (Excl. China)
18.48B18.24B---
Others (Excl. China) Growth
1.33%----
China
41.75B33.80B---
China Growth
23.55%----
Others
--55.84B49.86B42.91B
Others Growth
--12.00%16.21%6.14%
Total
398.83B314.56B555.54B560.04B515.95B
Total Growth
26.79%-43.38%-0.80%8.54%6.88%
Source: S&P Global Market Intelligence.